NRAS and acute myeloid leukemia: We observed a c-MYC protein decrease to a variable extent as early as 24h after treatment in all cell lines tested, including AML cell lines (NPM1-mutated OCI-AML3, BCR-ABL+ K562, PML-RARα-rearranged NB4, MLL-AF9 fused NOMO1 and NRAS-driven HL60), and ALL cell lines (T-ALL JURKAT and MLL-AF4 fused B-ALL RS4-11 cells) (Figure 3B, supplementary Figure 2A).